公开(公告)号：US20160368958A1

公开(公告)日：2016-12-22

申请号：US15197278

申请日：2016-06-29

Applicant: OncoTherapy Science, Inc.

Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

IPC: C07K14/47 ,  C07K16/18

CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

公开(公告)号：US20200155596A1

公开(公告)日：2020-05-21

申请号：US16773487

申请日：2020-01-27

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YAMASHITA ,  Tomohisa WATANABE ,  Tetsuro HIKICHI

IPC: A61K35/14 ,  C12N15/09 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C07K16/18 ,  A61K48/00 ,  A61K39/00 ,  A61K35/12

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20150017193A1

公开(公告)日：2015-01-15

申请号：US14500877

申请日：2014-09-29

Applicant: Oncotherapy Science, Inc.

Inventor： Yasuharu NISHIMURA ,  Katsunori IMAI ,  Yusuke NAKAMURA ,  Takuya TSUNODA

IPC: A61K39/00 ,  A61K38/16

CPC classification number: A61K39/00 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0387 ,  A61K38/16 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/47 ,  C07K14/4748 ,  C12N9/14 ,  C12N2799/027 ,  C12Y306/04004

Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.

Abstract translation: 本发明提供了包含选自SEQ ID NO：3,4和5的氨基酸序列的寡肽。本发明还提供含有选自SEQ ID NO：3,4和5的氨基酸序列的药物组合物。 3，4和5配制用于治疗或预防受试者的癌症。 此外，本发明提供使用这种寡肽和药剂诱导免疫应答的方法。

公开(公告)号：US20140141028A1

公开(公告)日：2014-05-22

申请号：US14171532

申请日：2014-02-03

Applicant: Oncotherapy Science, Inc.

Inventor： Takuya TSUNODA ,  Ryuji OHSAWA

IPC: C07K7/06

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K14/4747 ,  C12N5/0638 ,  C12N9/12 ,  C12N2502/11 ,  C12N2510/00 ,  C12Y207/10002 ,  C12Y207/11001

Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

Abstract translation: 根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。 因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸 取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。 此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。 本发明的药剂包括疫苗。

公开(公告)号：US20170198010A1

公开(公告)日：2017-07-13

申请号：US15412760

申请日：2017-01-23

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE ,  Gaku NAKAYAMA

IPC: C07K7/06 ,  C12N5/0783 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  C07K14/705 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/1114 ,  C12N2502/1121 ,  G01N33/57407

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

公开(公告)号：US20150322112A1

公开(公告)日：2015-11-12

申请号：US14648433

申请日：2013-12-02

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

IPC: C07K7/06 ,  G01N33/50 ,  C07K16/18

CPC classification number: C07K7/06 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/53 ,  C07K14/4703 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/34 ,  G01N33/505

Abstract: Peptide vaccines against cancer are described herein. Isolated epitope peptides derived from the SEMA5B gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The peptides encompass both SEMA5B-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for use in cancer immunotherapy.

Abstract translation: 本文描述了针对癌症的肽疫苗。 提供了衍生自引起CTL的SEMA5B基因并因此适用于癌症免疫治疗的上下文中的分离的表位肽。 肽包括SEMA5B衍生肽和其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持原始序列的必需的CTL诱导性。 还提供了编码这种肽的多核苷酸以及包括任何这样的肽或作为活性剂的多核苷酸的药物组合物。 还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。 此外，本发明提供了用于癌症免疫治疗的方法。

公开(公告)号：US20140199336A1

公开(公告)日：2014-07-17

申请号：US14221721

申请日：2014-03-21

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

IPC: C07K7/06

CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  C07K14/705

Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.

Abstract translation: 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

公开(公告)号：US20170333476A1

公开(公告)日：2017-11-23

申请号：US15501125

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE ,  TETSURO HIKICHI

IPC: A61K35/14 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C12N15/09 ,  C07K16/18 ,  A61K39/00 ,  A61K48/00

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20160101171A1

公开(公告)日：2016-04-14

申请号：US14924546

申请日：2015-10-27

Applicant: Oncotherapy Science, Inc.

Inventor： Takuya TSUNODA ,  Ryuji OHSAWA

IPC: A61K39/00 ,  C12N5/0783 ,  C12N9/12

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K14/4747 ,  C12N5/0638 ,  C12N9/12 ,  C12N2502/11 ,  C12N2510/00 ,  C12Y207/10002 ,  C12Y207/11001

Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

Abstract translation: 根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。 因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸 取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。 此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。 本发明的药剂包括疫苗。

公开(公告)号：US20160008445A1

公开(公告)日：2016-01-14

申请号：US14772003

申请日：2014-03-11

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  G01N33/505 ,  G01N33/57484

Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic- or post-operative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from KNTC2, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract translation: 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自KNTC2基因的分离的表位肽，其引发CTL并因此适用于癌症免疫治疗的上下文中。 本发明的肽包括来自KNTC2的多肽及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持原始序列的必需的CTL诱导性。 还提供了编码这种肽的多核苷酸以及包括任何这样的肽或作为活性剂的多核苷酸的药物组合物。 还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。 此外，本发明提供了用于治疗和/或预防（即预防）癌症（肿瘤）和/或预防其转移或手术后复发的方法以及诱导CTL的方法，方法 用于诱导抗肿瘤免疫，使用衍生自KNTC2的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。